

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A01/2017 OS

DESPATCHED ON 31ST JANUARY 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A3; B7, B57; Cw6, Cw7; DR7, DR15; DQ6, DQ9

				Summary of Results													
				PBL				T-Cells				B-Cells					
				14	14	13	13	37	38	37	33	37	37	36	33		
				13	6	0	1	32	2	0	5	31	34	2	8		
				1	8	13	12	5	36	37	28	6	3	34	25		
				1	1	2	2	1	0	1	5	2	2	3	7		
				92.9%	42.9%	0.0%	7.7%	86.5%	5.3%	0.0%	15.2%	83.8%	91.9%	5.6%	24.2%		
				7.1%	57.1%	100.0%	92.3%	13.5%	94.7%	100.0%	84.8%	16.2%	8.1%	94.4%	75.8%		
Consensus				Positive	Not Assessed	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
HLA Antibody Specificity (Defined By CDC)				A3	A10, B16, DQ1	B44, Cw5, DR4	?Bw6	A3	A10, B16, DQ1	B44, Cw5, DR4	?Bw6	A3	A10, B16, DQ1	B44, Cw5, DR4	?Bw6		
				Without DTT				Without DTT				Without DTT					
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments	
101	YES	YES	YES	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
112	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
114	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Positive	Negative	Positive		
116	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
119	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
120	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
128	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
133	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
139	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
143	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
145	YES	YES	YES	Positive	Negative	Negative	Negative	Equivocal	Negative	Negative	Negative	Positive	Positive	Negative	Equivocal		
147	YES	YES	YES	Positive	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
154	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative		
157	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative		
159	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Equivocal	Positive	Positive	Negative	Positive		
162	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
163	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
169	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
181	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Positive	Negative	Positive		
186	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
189	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
190	YES	YES	YES	NT	NT	NT	NT	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
193	YES	YES	YES	NT	NT	NT	NT	Positive	Negative	Negative	Positive	Positive	Positive	Negative	Positive	Not enough cells (aggregates)	
194	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
195	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
197	YES	YES	YES	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative		
204	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Positive		
206	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Equivocal	Positive	Positive	Negative	Positive	Serum 4 give positive reaction on T-cells only with 1µL injections (neg with 0.5µL) so we reported equivocal	
209	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	NT	NT	NT	NT	Technical problem	
216	YES	YES	YES	Negative	Negative	Equivocal	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	Unable to dissolve cell pellet for T and B-cells	
223	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative		
227	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	NT	NT	
229	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	NT	NT	
232	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	NT	NT	
235	YES	YES	YES	Positive	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	NT	NT	
238	YES	YES	YES	Positive	Negative	Negative	Equivocal	Positive	Negative	Negative	Equivocal	Positive	Positive	Negative	Equivocal	High mortality for LB	
239	YES	YES	YES	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative		
245	YES	YES	YES	Positive	Positive	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Positive	Negative	Positive		
252	YES	YES	YES	Positive	Positive	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Positive	Negative	Negative		
259	YES	YES	YES	Positive	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
260	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Equivocal	No results returned	
262	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Equivocal		
268	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
284	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Equivocal	Positive	Positive	Negative	Negative	T-cell crossmatch equivocal with serum 4: Positive results score 4 with anti-globulin test	
292	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
293	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative		
294	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative		
297	YES	YES	YES	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Negative	Negative	Positive	Negative	Negative		
321	YES	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Positive	NT	NT	NT	NT	Failure with B cells sorting	
351	YES	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Positive	Negative	Positive	NT	
				Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Number of B-cells were low	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A01/2017 OS

DESPATCHED ON 31ST JANUARY 2017

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101					1	1	1	1	1	8	1	1	60		
112	8	1	1	1											
114					8	1	1	1	8	8	1	2			
116					4-8	1	1	1-6	4-8	8	1	1-6	95	100	95
119	8	1	1	1											
120					8	1	1	1	6	8	1	1		100	100
128	8	1	1	1											
133					100	Neg	Neg	Neg	100	100	Neg	Neg	98	100	70
139	8	1	1	1	8	1	1	1	8	8	1	1	80	80	80
143					8	2	1	1						>90	
145									8	8				100	100
147	8	4	1	1	8	1	1	1	8	8	1	1	100	100	95
154					6	1	1	1	8	1	1	1	99	99	99
157					1	1	1	1	1	1	6	1	100	100	100
159					8	1	1	2	8	8	1	4	99	99	
162					8, 6				8, 6	8			95	90	
163					1	1	1	1	1	8	1	1	95	95	
169					8	1	1	1	8	8	1	1	98	98	
181					8	2	1	4	8	8	1	6	95	95	
186					8	0	0	0	8	8	0	0	99	99	
189	4	2	1	1									90		
190					5	5	5	5	30	100	5	5		95	95
193	NT	NT	NT	NT	8	1	1	6	6	8	1	4		100	98
194															
195					8	1	1	1	8	8	2	2	80		70
197						Weak			Weak				90	80	80
204					6	2	1	2	8	8	4	6		90	75
206					8	1	1	4	8	8	1	4		90	90
209					6	1	1	1	NT	NT	NT	NT		80	80
216	1	1	2	1									93		
223					8	2	1	2	8	8	8	4		97	97
227					8				6	8				90	90
229															
232					50	0	0	0						80	
235	8	4	1	1									85		
238	8	1	1		8	1	1		8	8	1		98	99	50
239	+++	++++			+++	++++			+++	++++			90	90	90
245	8	2	1	4	8	1	1	4	8	8	1	4	100	100	100
252	6	4	1	1					6	4-6	1	1	70		60
259															
260					8	0	0	0	8	8	0	2		90	90
262	6	1	1	1	8	1	1	1	8	8	1		88		
268					8	1	1	1	4	8	1	1		90	90
284					8	1	1	4	6	8	1	1		95	95
292					4				4	8				90	35
293					8+	0	0	0	8+	0	0	0	70	70	7
294					4	0	0	2	0	8	0	0		100	99
297	8	1	1	6	8	1	1	6	NT	NT	NT	NT	75	75	
321					1	1	1	1	1	8	1	4		80	75
351					4	2	2	2	2	6	2	1	90	90	75

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A01/2017 OS

DESPATCHED ON 31ST JANUARY 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A3; B7, B57; Cw6, Cw7; DR7, DR15; DQ6, DQ9

				Summary of Results												
				PBL				T-Cells				B-Cells				
				12	12	11	11	32	33	32	27	34	34	32	30	
				10	5	0	2	26	1	0	3	28	32	1	7	
				2	7	11	9	6	32	32	24	6	2	31	23	
				1	1	2	2	2	1	2	7	2	2	4	6	
				83.3%	41.7%	0.0%	18.2%	81.3%	3.0%	0.0%	11.1%	82.4%	94.1%	3.1%	23.3%	
				16.7%	58.3%	100.0%	81.8%	18.8%	97.0%	100.0%	88.9%	17.6%	5.9%	96.9%	76.7%	
				Positive	Not Assessed	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
				A3	A10, B16, DQ1	B44, Cw5, DR4	?Bw6	A3	A10, B16, DQ1	B44, Cw5, DR4	?Bw6	A3	A10, B16, DQ1	B44, Cw5, DR4	?Bw6	
				With DTT				With DTT				With DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
101		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
112	YES			Positive	Negative	Negative	Positive	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
114		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Negative	Positive	
116		YES	YES					Positive	Negative	Negative	Positive	Positive	Positive	Negative	Positive	
119	YES			Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
120		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
133		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
139	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
143		YES	YES					NT	NT	NT	NT	Positive	Positive	Negative	Negative	
147	YES	YES	YES	Positive	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
157		YES	YES					Positive	Negative	Negative	Equivocal	Negative	Positive	Positive	Negative	
159		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Negative	Positive	
162		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
163		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
169		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
181		YES	YES					Positive	Negative	Negative	Positive	Positive	Positive	Negative	Positive	
186		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
189	YES			Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
190		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
193	YES	YES	YES	NT	NT	NT	NT	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	Not enough cells (aggregates)
194		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
195		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
197	YES	YES	YES	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
204		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Negative	Positive	
206		YES	YES					Positive	Negative	Negative	Equivocal	Positive	Positive	Negative	Positive	
209		YES	YES					Positive	Negative	Negative	Negative	NT	NT	NT	NT	
216	YES			Negative	Negative	Equivocal	Negative	Positive	Negative	Negative	Negative	Positive	Positive	NT	NT	Technical problem
227		YES	YES					Positive	Negative	NT	NT	Positive	Positive	NT	NT	Unable to dissolve cell pellet for T and B-cells
229	YES															Technical failure
235	YES															No results returned
238	YES	YES	YES	Positive	Positive	Negative	Negative	Positive	Negative	Negative	Equivocal	Positive	Positive	Negative	Equivocal	High mortality for LB
245	YES	YES	YES	Positive	Positive	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Positive	Negative	Positive	
252	YES	YES	YES	Positive	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
260		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Negative	Equivocal	
262	YES	YES	YES	Positive	Negative	Negative	Negative	Equivocal	Negative	Negative	Negative	Positive	Positive	Negative	Equivocal	
268		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
284		YES	YES					Positive	Negative	Negative	Equivocal	Positive	Positive	Negative	Negative	
292		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Equivocal	Negative	
293		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	T-cell crossmatch equivocal with serum 4: Positive results score 4 with anti-globulin test
294		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
297	YES	YES	YES	Positive	Negative	Negative	Equivocal	Positive	Negative	Negative	Equivocal	Negative	Positive	Negative	Negative	
321	YES	YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	Failure with B-cell sorting
351	YES	YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Results returned with reservation

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A01/2017 OS

DESPATCHED ON 31ST JANUARY 2017

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101					1	1	1	1	1	8	1	1			
112	8	1	1	4									60		
114					8	1	1	1	8	8	1	1			
116					2-8	1	1	1-6	2-8	6-8	1-2	1-6		100	95
119	1	1	1	1									95		
120					8	1	1	1	8	8	1	1		100	100
133					100	Neg	Neg	Neg	100	100	Neg	Neg	88	100	70
139	8	1	1	1	8	1	1	1	8	8	1	1	80	80	80
143					NT	NT	NT	NT						>90	
147	8	4	1	1	8	1	1	1	8	8	1	1		100	95
157									1	1	4	1	100	100	100
159					8	1	1	2	8	8	1	4		99	99
162					8, 6				8, 6	8				95	90
163					1	1	1	1	1	8	1	1		95	95
169					4	1	1	1	6	8	1	1		98	98
181					8	2	1	4	8	8	1	6		95	95
186					8	0	0	0	8	8	0	0		99	99
189	4	2	1	1									90		
190					5	5	5	5	40	100	5	5		95	95
193	NT	NT	NT	NT	8	1	1	2	6	8	1	2		100	98
194															
195					8	1	1	1	8	8	2	2	80		70
197						Weak			Weak				90	80	80
204					6	2	1	2	8	8	4	6		90	75
206					8	1	1	4	6	8	1	4		90	90
209					4	1	1	1	NT	NT	NT	NT		80	80
216	1	1	2	1									93		
227					8				6	8				90	90
229															
235	8	4	1	1									85		
238	8	1	1		8	1	1		8	8	1		98	99	50
245	8	2	1	4	8	1	1	4	8	8	1	6	100	100	100
252	6	4	1	1					6	4-6	1	1	70		60
260					0	0	0	0	8	8	0	2		90	90
262	4	1	1	1		1	1	1	8	8	1		88		
268					8	1	1	1	4	8	1	1		90	90
284					8	1	1	4	8	8	1	2		95	95
292					4				4	8	2			90	35
293					8+	0	0	0	8+	0	0	0	70	70	7
294					6	2	0	0	0	8	0	0		100	99
297	8	1	1	2-4	8	1	1	2-4	NT	NT	NT	NT	75	75	
321					1	1	1	1	1	8	1	4		80	70
351					2	2	2	2	2	6	2	2	90	90	75